Immunovant
NASDAQ · IMVT·New York, NY·Mid-cap·Phase 3
Clinical-stage biopharma developing batoclimab and IMVT-1402, anti-FcRn antibodies for IgG-mediated autoimmune diseases. Multiple Phase 3 programs across myasthenia gravis, Graves' disease, thyroid eye disease, and CIDP.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Immunovant Master Deck February 2026 | Corporate overview | February 10, 2026 | 67 |